Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

Andrew M. Evens, DO, MSc, Julie M Vose, MD, MBA, Wael Harb, MD, Leo I. Gordon, MD, Robert Langdon, MD, Barbara Grant, MD, Julian Sprague, MD, PhD, Clara Plasencia, MS, Mint Sirisawad, MS, Jeanne Yue, MS, Ying Luan, PhD, Aaron Siek, BS, Lei Zhou, MD, Sriram Balasubramanian, PhD, Nancy L. Bartlett, MD

Blood (2012) 120 (21): 55.

https://doi.org/10.1182/blood.V120.21.55.55

Published: 2012

Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Inhibits Growth of ABC DLBCL Tumors In Vivo and in Vitro by Preventing Activation of Pro-Survival NF-κB pathways

Sriram Balasubramanian, PhD, Richard Crowley, MS, Mint Sirisawad, MS, Patti Thiemann, MS, Jun Chen, PhD, Joseph J. Buggy, PhD

Blood (2011) 118 (21): 4969.

https://doi.org/10.1182/blood.V118.21.4969.4969

Published: 2011

Journal Articles

The Histone Deacetylase (HDAC) Inhibitor PCI-24781 Decreases Pro-Inflammatory Cytokine Secretion In Vitro and In Vivo and Protects Against Endotoxemia In a Sepsis Model

Sriram Balasubramanian, PhD, Mint Sirisawad, MS, Susanne Steggerda, PhD, Wangsen Cao, MD, PhD, Charles Lowenstein, MD, Joseph J Buggy, PhD

Blood (2010) 116 (21): 3914.

https://doi.org/10.1182/blood.V116.21.3914.3914

Published: 2010

Journal Articles

Development of RAD51 as Biomarker for Sensitivity to the Histone Deacetylase (HDAC) Inhibitor PCI-24781 in Lymphoma.

Sriram Balasubramanian, PhD, Shanthi Adimoolam, PhD, Mint Sirisawad, MS, Andrew M. Evens, DO, Leo I. Gordon, MD, Richard Miller, MD, Joseph J. Buggy, PhD

Blood (2007) 110 (11): 1377.

https://doi.org/10.1182/blood.V110.11.1377.1377

Published: 2007

Journal Articles

Histone Deacetylase Inhibitor, PCI-24781, Induces Growth Inhibition and Apoptosis in Hematopoietic Tumor-Derived Cell Lines and Primary Leukemia Cells.

Joseph Buggy, PhD, Sriram Balasubramanian, PhD, Jason Ramos, PhD, Mint Sirisawad, MS, Louie Naumovski, MD, PhD

Blood (2006) 108 (11): 4399.

https://doi.org/10.1182/blood.V108.11.4399.4399

Published: 2006

NARROW

A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Inhibits Growth of ABC DLBCL Tumors In Vivo and in Vitro by Preventing Activation of Pro-Survival NF-κB pathways

The Histone Deacetylase (HDAC) Inhibitor PCI-24781 Decreases Pro-Inflammatory Cytokine Secretion In Vitro and In Vivo and Protects Against Endotoxemia In a Sepsis Model

Development of RAD51 as Biomarker for Sensitivity to the Histone Deacetylase (HDAC) Inhibitor PCI-24781 in Lymphoma.

Histone Deacetylase Inhibitor, PCI-24781, Induces Growth Inhibition and Apoptosis in Hematopoietic Tumor-Derived Cell Lines and Primary Leukemia Cells.

Email alerts

ASH Publications

American Society of Hematology

A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Inhibits Growth of ABC DLBCL Tumors In Vivo and in Vitro by Preventing Activation of Pro-Survival NF-κB pathways

The Histone Deacetylase (HDAC) Inhibitor PCI-24781 Decreases Pro-Inflammatory Cytokine Secretion In Vitro and In Vivo and Protects Against Endotoxemia In a Sepsis Model

Development of RAD51 as Biomarker for Sensitivity to the Histone Deacetylase (HDAC) Inhibitor PCI-24781 in Lymphoma.

Histone Deacetylase Inhibitor, PCI-24781, Induces Growth Inhibition and Apoptosis in Hematopoietic Tumor-Derived Cell Lines and Primary Leukemia Cells.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only